Sen. Alexander Questions FDA's Slow Response To WEN Complaints
This article was originally published in The Rose Sheet
Executive Summary
In a letter to FDA leadership, Sen. Lamar Alexander, R-Tenn., asks the agency to explain its current regulatory authorities over cosmetics and limitations under current law, as well as how it handles adverse-event reports and takes action against non-compliant products. Alexander chairs the Senate HELP Committee and raised concerns at a recent hearing about FDA’s response to WEN.
You may also be interested in...
FDA Eyeing Study On Cosmetic Hair-Care/Hair-Loss Link
Interested parties capable of conducting in vivo and in vitro tests "to study alopecia that may be associated with the use of commercially available cosmetic hair products and individual ingredients in these products" must respond to FDA's Sources Sought Notice by Feb. 26.
Cosmetics Adverse Events Under Spotlight In FDA Transparency Push
FDA’s release of AER data removes some secrecy surrounding cosmetic product adverse events but could create a false alarm about the industry. The data dump comes as Congress is considering legislation that would mandate that cosmetics firms provide FDA with reports of serious adverse events they receive.
Consumers, Health Practitioners Heeded FDA’s Call For WEN-Related AEs
FDA’s safety alert in July, asking WEN users and their doctors to share information regarding hair loss-related adverse events, yielded approximately 1,000 reports in just over two months, contributing to a massive increase in cosmetic AE reports for FY 2016.